Effects of PACAP in the Local Regulation of Endocrine Glands

International audience; Pituitary adenylate cyclase-activating polypeptide (PACAP), a peptide of the vasoactive intestinal polypep-tide (VIP)-glucagon superfamily, was initially characterized by virtue of its ability to stimulate cAMP formation in cultured rat anterior pituitary cells. Three PACAP receptors have been cloned so far: a PACAP-selective receptor, termed PAC1-R, and two PACAP/VIP common receptors, termed VPAC1-R and VPAC2-R. PACAP and its receptors are widely expressed in the brain and in peripheral organs, notably in the hypothalamus and in endocrine glands. Indeed, there is now clear evidence that PACAP exerts neuroendocrine, paracrine, and autocrine control of the activity of the pituitary, thyroid, testis, ovary, adrenal medulla, adrenal cortex, and endocrine pancreas. These observations suggest that selective PACAP agonists and antagonists could have therapeutic value for the treatment of various endo-crine disorders.